Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation? [Yahoo! Finance]
ProQR Therapeutics (NASDAQ: PRQR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration [Yahoo! Finance]